A Phase 3 interventional study of CT-P55 and EU-approved Cosentyx in Plaque Psoriasis, sponsored by Celltrion. Active, not recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by Celltrion · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 166 studies in Psoriasis with a site in Poland — 7 open to participants now, 20 under way, 18 of them phase 3. Psoriasis · Poland.
Among the 166 studies in Psoriasis with a site in Poland, this one is the 128th largest by enrollment of the 162 interventional ones that give a count, is one of 12 that started in 2025, is one of 106 in phase 3, reaches primary completion later than 8 of the 19 other live ones, and was the 156th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →7 of the 166 studies in Psoriasis with a site in Poland are open now. Recruiting first, the newest first:
Takeda · Sites in Poland, United States, China and 4 more countries
Ages 4–17
Bristol-Myers Squibb · Sites in Poland, United States, Argentina and 13 more countries
Ages 12–17
Chong Kun Dang Pharmaceutical · Sites in Poland
Ages 18–55 · Healthy volunteers
UCB Biopharma SRL · Sites in Poland, United States, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Poland, United States, Argentina and 22 more countries
Ages 40+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
166 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 40 · Phase 3 108 · Phase 4 9
First in 2002; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 376 across the 162 interventional studies, 2,032 across the 4 observational. Of the 145 that completed or were terminated, 111 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
162 of 166 have an industry lead sponsor. The 10 most frequent:
Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.
Celltrion has 4 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
1 of the studies in Psoriasis with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013201LEO PharmaA 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis | 2027-06-04 |
Add it to your calendar (.ics) → With an account.
Among the 166 studies in Psoriasis with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P55 with Cosentyx in patients with moderate to severe plaque psoriasis
CT-P55 is a recombinant humanized monoclonal antibody containing the active ingredient secukinumab. CT-P55 is a drug product being developed by CELLTRION, Inc. and being compared to the EU-approved Cosentyx®. In this study, Efficacy and Safety of CT-P55 will be evaluated in patients with Moderate to Severe Chronic Plaque Psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Patient has had a diagnosis of chronic plaque psoriasis for at least 24 weeks.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: CT-P55
Biological: CT-P55 · Biological: EU-approved Cosentyx
CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).
European Union (EU)-approved Cosentyx, 300 mg by 2 SC injections of 150 mg/mL via PFS every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by Q4W for 11 doses (up to Week 48).
Percent change from baseline in Psoriasis Area and Severity Index (PASI) score
A higher percent change indicates a better outcome. While the maximum value is 100%, the minimum value is not fixed and may be negative in cases of worsening symptoms.
Time frame: Week8
Actual PASI scores
Minimum 0 to Maximum 72 Higher scores mean a worse outcome
Time frame: Up to 56 Weeks
Percent change from baseline in PASI score
A higher percent change indicates a better outcome. While the maximum value is 100%, the minimum value is not fixed and may be negative in cases of worsening symptoms.
Time frame: Up to 56 Weeks
Proportion of patients who achieve at least 50/75/90/100% improvement from baseline in PASI (PASI 50/75/90/100)
Time frame: Up to 56 Weeks
Proportion of patients with Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1)
Time frame: Up to 56 Weeks
Change from baseline in Dermatology Life Quality Index (DLQI)
Minimum -30 to Maximum of 30 Higher scores indicate a worse outcome
Time frame: Up to 56 Weeks
Ran from May 2025 to primary completion in Feb 2026, 8 months.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 8 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.